Got $5,000? Rocket Lab Stock Could Be the Space Launch Upstart Investors Kick Themselves for Ignoring by 2035

Rocket Lab reported Q1 revenue of $200.3 million, up 63.5% year over year and well ahead of analyst expectations, while gross margin hit a record 38.2%. Management guided Q2 revenue to as high as $240 million, implying roughly 66% growth, and the company added 31 Electron launches plus five Neutron launches to backlog. Analysts now expect $867 million in 2026 revenue and about $8.8 billion by 2035, but the stock remains expensive at roughly 67x trailing sales.

Analysis

RKLB’s beat is more important as a credibility event than as a single-quarter growth print: the market is re-rating the company from a “one-asset launch story” toward a multi-product industrial platform. The second-order implication is that backlog quality likely matters more than near-term revenue, because each incremental launch order also pulls through propulsion, satellite components, and defense-adjacent systems, improving mix and lifetime customer value. If management can convert this into a steadier cadence of repeat contracts, the multiple can stay elevated even before Neutron contributes meaningfully.

The key swing factor is execution timing on Neutron. A large share of the long-duration upside is already being capitalized into the stock, so the next incremental valuation leg likely requires evidence that Neutron is not just sold, but de-risked on schedule; otherwise the stock becomes hostage to “promise premium” compression. A miss or delay would not just hit sentiment — it would likely force investors to re-underwrite the whole growth stack, because the market is implicitly pricing a future where launch capacity expands without proportionate margin dilution.

The contrarian issue is that this is still a capital-hungry business with an expensive equity currency, so the path to sustained outperformance may be through selective monetization of strength, not blind holding. The most interesting setup may be around volatility rather than direction: after a sharp post-earnings move, the stock can remain strong if guidance revisions keep compounding, but if estimates stop rising, the forward multiple is vulnerable to mean reversion. RTX benefits as a program-validation partner, but the economic torque is far smaller; the real read-through is defense optionality, not direct earnings lift.

Near term, the stock can continue to trade on estimate momentum for several quarters; over 12-24 months, the debate shifts to whether Neutron and adjacent products turn growth into operating leverage. Until then, the risk/reward is asymmetrical only if you believe revisions will outrun valuation expansion — otherwise, the stock is already discounting a very high success rate.

Key Decisions for Investors

• Maintain a tactical long in RKLB only on post-earnings strength, but use trailing stops; the setup favors momentum over 1-3 months, while the valuation leaves little room for guidance disappointment.
• For new capital, prefer a call spread in RKLB over outright equity exposure into the next 1-2 quarters; this captures estimate revision upside while capping damage if the multiple compresses.
• Consider a pair trade: long RKLB / short a broad high-multiple software or unprofitable growth basket over 3-6 months, betting that positive execution can outperform duration-sensitive names if rates stay sticky.
• Add RTX only as a small satellite position if you want defense-program optionality; the read-through is modest and better treated as a lower-vol way to express the theme.
• Set a risk trigger on RKLB around any Neutron schedule slippage or backlog conversion slowdown; if either appears, reduce exposure quickly because the market is pricing in near-perfect execution.